BBP: A Diversified Biotech ETF

While 2017 has been a pretty good year overall for biotechs - the two largest ETFs in the space, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the SPDR S&P Biotech ETF (NYSEARCA:XBI), are up 10% and 17%, respectively - it's tough to forget that both of these funds are still about 25% off of their 2015 highs. IBB, which is heavily influenced by the largest biotech names, has been impacted by 50% drops in Gilead (NASDAQ:GILD) and Biogen (NASDAQ:BIIB). XBI has a much more diversified all-cap mix but has experienced similar results.

But not all news coming out of the sector is bad. In fact, one biotech ETF has been downright ripping it since its launch at the end of 2014. The BioShares Biotechnology Products ETF (NASDAQ:BBP), which invests in companies that have at least one primary product that's received FDA approval, is up roughly 42% since its inception at the end of 2014 compared to a loss of 4% for IBB during the same time frame.

Click the button below to read the rest of this original article on Seeking Alpha.

If you enjoyed reading this article, please be sure to share it below and subscribe to the site so that you don't miss any updates or new stuff! As always, thank you for taking the time to read!

Become A GREAT Dividend Growth Investor!

Sign up to receive our FREE 6-part guide on how to pick the right stocks, invest with conviction and secure a stress-free retirement today!

    We won't send you spam. Unsubscribe at any time.